VYGR (Voyager Therapeutics) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYGR Voyager Therapeutics Inc VYGR
43 GF Score
Price $3.13
GF Value $1.28
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics SpecialCharges?

Special Charges only applies to banks.

VYGR
43GF Score
Voyager Therapeutics Inc VYGR
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Voyager Therapeutics (VYGR) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of $3.13 is trading 144.5% above its estimated GF Value™ of $1.28. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for VYGR:

  • SpecialCharges:
  • GF Value™: $1.28 vs. price of $3.13 (144.5% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Voyager Therapeutics Business Description

Other Exchanges VYGR:MexicoVT6:Germany
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for neurological diseases. Its pipeline targets conditions such as Parkinson's disease, Alzheimer's disease, Friedreich's ataxia, Huntington's disease, and other central nervous system disorders. Many programs are built on the company's TRACER adeno-associated virus (AAV) capsid discovery platform, which generates novel capsids designed to enable high brain penetration following intravenous dosing. Voyager also develops antibody-based and other genetic medicines. The company operates through a single segment, developing and commercializing genetic medicines. It generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical partners, including Neurocrine Biosciences and Novartis, which fund research and development in exchange for rights to certain programs. Voyager is headquartered in Cambridge, Massachusetts, and its activities are concentrated in the United States.
43GF Score

Get the complete analysis for VYGR

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.13
Price
$1.28
GF Value